Sensorion SA (ALSEN)

Currency in EUR
5.9900
+0.2950(+5.18%)
Real-time Data·
Advertisement
ALSEN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5.70106.2630
52 wk Range
5.249040.4000
Key Statistics
Prev. Close
5.695
Open
5.701
Day's Range
5.701-6.263
52 wk Range
5.249-40.4
Volume
9.24K
Average Volume (3m)
18.64K
1-Year Change
-67.882%
Book Value / Share
7.92
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ALSEN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
40.2000
Upside
+571.12%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

Sensorion SA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 40.2000
(+571.12% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy32.00+431.56%-Upgrade24/09/2026
Baird
Buy1.75-70.93%2.00Maintain11/06/2026
Stifel
Buy1.10-81.73%1.50Maintain10/03/2026

Earnings

Latest Release
23/09/2026
EPS / Forecast
-2.28 / -0.12
Revenue / Forecast
1.75M / 872.5K
EPS Revisions
Last 90 days

Compare ALSEN to Peers and Sector

Metrics to compare
ALSEN
Peers
Sector
Relationship
P/E Ratio
−1.7x−3.1x−0.3x
PEG Ratio
−0.28−0.030.00
Price/Book
0.7x0.3x2.6x
Price / LTM Sales
9.5x10.1x2.9x
Upside (Analyst Target)
-309.9%64.3%
Fair Value Upside
Unlock3.2%9.9%Unlock

Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies. It is also developing SENS-40, a small molecule in Phase 2b clinical trials to treat sudden sensorineural hearing loss; prevention of residual hearing loss following cochlear implantation in Phase 2a clinical trials; and prevention of cisplatin-induced ototoxicity in Phase 2a clinical trials. The company was incorporated in 2009 and is headquartered in Montpellier, France.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
669.22K6.49%3.77M
Other Institutional Investors
0.000.00%0.00
Public Companies & Retail Investors
9.64M93.51%54.35M
Total
10.3M100.00%58.12M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
FMR LLC3.33%343,4771,937
Fidelity Select Portfolios - Biotechnology Portfolio3.33%343,4771,937

People Also Watch

0.7340
ALHAF
0.00%
40.45
ALSEM
+0.50%
0.0130
ALTAO
-1.52%
0.1108
ALTME
+2.97%

FAQ

What Is the Sensorion SA (Paris: ALSEN) Share Price Today?

The Sensorion SA stock price today is 5.9900 EUR.

What Stock Exchange Does Sensorion SA (ALSEN) Trade On?

Sensorion SA is listed and trades on the Paris Stock Exchange.

What Is the Ticker (Stock Symbol) for Sensorion SA?

The stock symbol (also called a 'ticker') for Sensorion SA is "ALSEN."

What Is the Current Sensorion SA Market Capitalisation?

As of today, Sensorion SA (Paris: ALSEN) market cap is 61.6400M EUR.

What Is Sensorion SA's (ALSEN) Earnings Per Share (TTM)?

The Sensorion SA EPS is currently -4.36 (Trailing Twelve Months).

When Is the Next Sensorion SA Earnings Date?

Sensorion SA's next earnings report will be released on 02/12/2026.

Is ALSEN a Buy or Sell From a Technical Analyst Perspective?

Based on today's Sensorion SA moving averages and other technical indicators, the daily buy/sell signal for ALSEN stock is Strong Sell.

How Many Times Has Sensorion SA Stock Split?

Sensorion SA has split 1 times. (See the ALSEN stock split history page for full effective split date and price information.)

How Many Employees Does Sensorion SA Have?

Sensorion SA has 66 employees, based on their latest Companies House report.

What is the current trading status of Sensorion SA (Paris: ALSEN)?

As of 16/10/2026, Sensorion SA (ALSEN) is trading at a share price of 5.9900 EUR, with a previous close of 5.6950 EUR. The stock has fluctuated within a day range of 5.7010 EUR to 6.2630 EUR, while its 52-week range spans from 5.2490 EUR to 40.4000 EUR.

What Is Sensorion SA (ALSEN) Price Target According to Analysts?

The average 12-month price target for Sensorion SA is 40.2000 EUR, with a high estimate of 50 EUR and a low estimate of 32 EUR. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +571.12% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.